Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

• Authors: Changhai Ding
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 11 Pg. 1020-5 (Nov 2006) ISSN: 1472-4472 [Print] England
• PMID: 17117592 (Publication Type: Journal Article)

Chemical References

• Enzyme Inhibitors
• Phenylurea Compounds
• VX 702
• p38 Mitogen-Activated Protein Kinases

Topics

• Acute Disease
• Administration, Oral
• Arthritis, Rheumatoid (drug therapy)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Coronary Disease (drug therapy)
• Drug Evaluation
• Enzyme Inhibitors (administration & dosage, therapeutic use)
• Humans
• Patents as Topic
• Phenylurea Compounds (administration & dosage, pharmacology, therapeutic use)
• Syndrome
• p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)